Đogo, Aleksandar (57216950667)Aleksandar (57216950667)ĐogoStojanovic, Milos (58202803500)Milos (58202803500)StojanovicIvovic, Miomira (6507747450)Miomira (6507747450)IvovicTancic Gajic, Milina (25121743400)Milina (25121743400)Tancic GajicMarina, Ljiljana V. (36523361900)Ljiljana V. (36523361900)MarinaCitlucanin, Goran (57216956891)Goran (57216956891)CitlucaninBrkic, Milena (57209338804)Milena (57209338804)BrkicPopovic, Srdjan (58426757200)Srdjan (58426757200)PopovicVujovic, Svetlana (57225380338)Svetlana (57225380338)Vujovic2025-06-122025-06-122020https://doi.org/10.1080/09513590.2020.1768370https://www.scopus.com/inward/record.uri?eid=2-s2.0-85085497247&doi=10.1080%2f09513590.2020.1768370&partnerID=40&md5=937f0195741c04d16b5a530242672056https://remedy.med.bg.ac.rs/handle/123456789/4756Aim: to test effects of estradiol (E2) 1 mg and drospirenone (DRSP) 2 mg in treatment of normal weight menopausal women with typical menopausal symptoms, hyperinsulinism, and grade I hypertension. Material and methods: The participants were 133 menopausal women, mean age 51.82 ± 3.25 years, body mass index (BMI) 24.9 ± 2.6 kg/m2, waist/hip 0.80 ± 0.05, amenorrhoeic period 2.12 ± 2.10 years. All patients were treated with E2 1 mg and DRSP 2 mg during 12 months period. Blood samples were taken at 8 am before and during 12 months of therapy for: glycemia, lipids, hormonal analysis, follicle-stimulating hormone (FSH), luteinizing hormone (LH), E2, testosterone (T), prolactin (PRL), dehydroepiandrosterone sulfate (DHEAS), and sex hormone-binding globulin (SHBG). Oral glucose tolerance test (OGTT) was performed with 75 g glucose in order to assess insulin secretion. All had grade I hypertension 24 h blood pressure monitoring was performed before and after 12 months of therapy. Results: E2/DRSP significantly decreased total cholesterol, low-density lipoprotein (LDL), apolipoprotein B (ApoB), and increased high-density lipoprotein cholesterol (HDL) and apolipoprotein A (ApoA). Insulin area under the curve (AUC) significantly decreased (6586.1 ± 4194.2 vs. 5315.3 ± 2895.0, p <.05) and homeostatic model assessment (HOMA) (3.53 ± 2.18 vs. 3.0 ± 1.8, p <.05). FSH, LH decreased, E2 increased significantly. Of 24 h day blood pressure decreased significantly. Conclusions: E2/DRSP represents suitable therapy for hyperinsulinemic, grade I hypertensive menopausal women with typical symptoms and normal weight. © 2020 Informa UK Limited, trading as Taylor & Francis Group.drospirenoneestradiolHyperinsulinismhypertension grade Imenopause